The need for a disease-specific prospective pregnancy registry for multiple sclerosis (MS)

    Authors

    S. Alwan; C. D. Chambers; V. T. Armenti;A. D. Sadovnick

    Comments

    Authors: contact us about adding a copy of your work at STARS@ucf.edu

    Abbreviated Journal Title

    Mult. Scler. Relat. Disord.

    Keywords

    Multiple sclerosis; Pregnancy; Reproduction; Birth outcome; Pregnancy; registry; GLATIRAMER ACETATE EXPOSURE; MYCOPHENOLATE-MOFETIL; MITOXANTRONE; EXPOSURE; HUMAN TERATOGENICITY; DIAGNOSTIC-CRITERIA; INTERFERON BETA-1B; CONTROLLED-TRIAL; MODIFYING DRUGS; BIRTH OUTCOMES; FETAL OUTCOMES; Clinical Neurology

    Abstract

    Multiple sclerosis (MS) is the most commonly acquired neurological disorder affecting young adults of reproductive age with an approximately 3:1 female to male ratio. Although pregnancy is not contraindicated in MS, data are limited regarding pregnancy outcome among MS patients, and the safety or risk to the fetus associated with most maternal MS treatments, such as disease modifying therapies (DMTs), during pregnancy is unknown. We review available epidemiological and registry data on MS and pregnancy and discuss the need to initiate a North American Multiple Sclerosis Pregnancy Registry that will prospectively identify pregnancies in women with MS, obtain information on the disease, and its treatment during gestation and lactation and follow the children to determine their health status. (C) 2014 Elsevier B.V. All rights reserved.

    Journal Title

    Multiple Sclerosis and Related Disorders

    Volume

    4

    Issue/Number

    1

    Publication Date

    1-1-2015

    Document Type

    Review

    Language

    English

    First Page

    6

    Last Page

    17

    WOS Identifier

    WOS:000349666400003

    ISSN

    2211-0348

    Share

    COinS